

FIGURE 1


mAbs block binding of HL-60
to stimulated HUVEC at 37oC.
% Bound
60
50
40
30
20
10
0
IL-1B
mAb
0
+
+
+
+
+
+
+
no mAb
no mAb
FH6
SH-1
SNH-3
SNH-4
CSLEX-1
FH2

Fig. 2 A


mAb block binding of HL-60
to stimulated HUVEC at 4oC.
% Bound
60
50
40
30
20
10
0
IL-1B
mAb
0
+
+
+
+
+
+
+
no mAb
no mAb
FH6
SH-1
SNH-3
SNH-4
CSLEX-1
FH2

Fig. 2 B


Inhibition of LEC11 binding to activated endothelium by mAb.
% Bound
50
40
30
20
10
0
IL-1B mAb
-
+
+
+
+
+
+
+
no mAb
no mAb
FH6
SH-1
SNH-3
SNH-4
CSLEX-1
FH2

Fig. 3A


Inhibition of LEC12 binding to activated endothelium by mAb.
% Bound
50
40
30
20
10
0
IL-1B mAb
-
+
+
+
+
+
+
+
no mAb
no mAb
FH6
SH-1
SNH-3
SNH-4
CSLEX-1
FH2

Fig. 3B



Figure 4



Figure 5


Inhibition of platelet adhesion by mAb.
% cells bound
50
10
0
NO mAb
CSLEX-1
SNH-4
FH2
SH-1
HL-60
Jurkat

Figure 6


100
80
60
40
20
0
% cells bound
0
1
2
3
4
5
6
Conc. of Liposomes (ug/ml)
SPG
LeX (DiY2)
SLeX (SDiY2)

Figure 7


100
80
60
40
20
0
% cells bound
0
1
2
3
4
5
6
Conc. of Liposomes (ug/ml)
LeX(DiY2)
SPG
SLeX(6Di42)

Figure 8


Inhibition of GMP-140 Mediated Adhesion
of Neutrophils by Glycolipid with terminal
Sialic Acid either NeuAc or NeuGc
Cells with Bound Platelets (%)
100
80
60
40
20
0
0.0
1.0
2.0
Glycolipid (ug/ml)
SH
∝ 2,6 SLeX cer.
SLeX (hexa)
∝ 2,3 SLeX cer

Figure 9

Anti-ELAM-1 Protection of LPS Induced Lethality



Figure 10

08/063131


Anti-ELAM-1 Protection of LPS Induced Lethality In Rats
Survivors (%)
100
80
60
40
20
0
saline
J606
-1 hr
2 hrs
4 hrs
6 hrs
anti-ELAM -1

Figure 11



I



II



III



IV



V



VI



VII



VIII



IX



X



XI (Z)

FIGURE 12 A

Figure 12B
E-Selectin Cell Adhesion Assay

Compound Z



Compound Number	A	ratio Z IC_{50}/Compound IC_{50}
XII		0.92
XIII		0.87
XIV		1.0
XV		1.0
XVI		1.0

XVII		1.0
XVIII		1.0
XIX		1.0
XX		1.0
XXIII		2.0
XXIV		2.5
XXV		3.7
XXVI		3.7

XXI



5.7

XXII



2.28


Z inhibits the binding of HL-60 cells to recombinant E-selectin
1.5
1
0.5
0
Fraction of cells bound
Z
sLN
0.01
0.1
1
10
Concentration (mM)

Figure 13


The effect of histamine on the flux of rolling leukocytes
Flux of rolling leukocytes (sec⁻¹)
2
1.5
1
0.5
0
0
10⁻⁷
10⁻⁶
10⁻⁵
Histamine (M)
Panel A
The effect of histamine on the velocity of rolling leukocytes
Leukocyte rolling velocity (μm/sec)
60
40
20
0
0
10⁻⁷
10⁻⁶
10⁻⁵
Histamine (M)
Panel B
The effect of histamine on the number of rolling leukocytes
Number of rolling leukocytes (per 100 μm venule)
6
4
2
0
0
10⁻⁷
10⁻⁶
10⁻⁵
Histamine (M)
Panel C

Figure 14

The effect of selectin blockers on histamine (10^{-5} M)-induced flux of rolling leukocytes.



Panel A

The effect of selectin blockers on histamine (10^{-5} M)-induced leukocyte rolling velocity.



Panel B

The effect of selectin blockers on the number of histamine (10^{-5} M)-induced rolling leukocytes.



Panel C

Figure 15


The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on CVF-induced lung permeability
Permeability index
0.6
0.4
0.2
0
Frame A
PBS
CVF
SLN-OH
SLX-OH
The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on CVF-induced lung hemorrhage
Hemorrhage index
0.3
0.2
0.1
0
Frame B
PBS
CVF
SLN-OH
SLX-OH
The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on CVF-induced lung neutrophil accumulation
MPO content
0.6
0.4
0.2
0
Frame C
PBS
CVF
SLN-OH
SLX-OH

Figure 16


Z administration inhibits cobra venom factor-induced pulmonary vascular permeability
Permeability index
0.8
0.6
0.4
0.2
0
0
0.5
1
1.5
2
Z (mg/Kg)
Z
Panel A
Z administration inhibits cobra venom factor-induced pulmonary hemorrhage
Hemorrhage index
0.3
0.2
0.1
0
Z mg/Kg
Z
Panel B
Z administration inhibits cobra venom factor-induced pulmonary neutrophil sequestration
MPO activity
0.8
0.6
0.4
0.2
0
Z (mg/Kg)
Z
Positive control
Panel C

Figure 17

The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on IgG immune complex-induced lung permeability



The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on IgG immune complex-induced lung hemorrhage



The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on IgG immune complex-induced lung neutrophil accumulation



Figure 18


Z inhibits IgG immune complex-induced pulmonary vascular permeability
Permeability index
Panel A
Z (μg / dose)
Z inhibits IgG immune complex-induced pulmonary hemorrhage
Hemorrhage index
Panel B
Z (μg / dose)
Z inhibits IgG immune complex-induced pulmonary neutrophil sequestration
MPO activity
Panel C
Z (μg / dose)

Figure 19


The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on IgA immune complex-induced lung permeability
Permeability Index
0.5
0.25
0
Frame A
PBS
CVF
SLN-OH
SLX-OH


The effect of an SLe^x analog (SLX-OH) and a control oligosaccharide (SLN-OH) on IgA immune complex-induced lung hemorrhage
Hemorrhage Index
0.2
0.13
0.067
0
Frame B
PBS
CVF
SLN-OH
SLX-OH

Figure 20

The effect of Z on ischemia reperfusion induced myocardial necrosis in the cat



Figure 21